跳至主要内容
临床试验/NCT02459132
NCT02459132已完成不适用

A Phase II Randomized Trial of High-Intensity Aerobic Interval Training and Surrogate Markers of Cardiovascular Disease in a Population-based Sample of Testicular Cancer Survivors

University of Alberta0 个研究点目标入组 63 人开始时间: 2015年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
63
主要终点
Peak aerobic capacity (relative VO2peak)

研究概览

简要总结

This study evaluates the impact of a supervised 12-week high-intensity aerobic interval exercise program (versus a self-directed exercise usual care group) on traditional and novel cardiovascular disease risk factors and surrogate markers of cardiovascular- and overall-mortality in a population-based sample of testicular cancer survivors.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • histologically confirmed history of testicular cancer

排除标准

  • Not sufficiently ambulatory to complete the first two stages of the aerobic exercise test.
  • Have a psychiatric condition which impairs their ability to perform the required volume and intensity of exercise.
  • Have any uncontrolled cardiovascular condition (i.e. heart disease, hypertension, diabetes, arrhythmia).
  • Report performing any weekly vigorous intensity aerobic exercise in the past month.

结局指标

主要结局

Peak aerobic capacity (relative VO2peak)

时间窗: Baseline and within 7 days of completing the 12-week intervention

ml O2/kg/min

次要结局

  • Peak aerobic capacity (absolute VO2peak)(Baseline and within 7 days of completing the 12-week intervention)
  • Postexercise 1-minute heart rate recovery(Baseline and within 7 days of completing the 12-week intervention)
  • Average carotid intima-media thickness(Baseline and within 7 days of completing the 12-week intervention)
  • Carotid distensibility(Baseline and within 7 days of completing the 12-week intervention)
  • Velocity time integral(Baseline and within 7 days of completing the 12-week intervention)
  • Respiratory sinus arrhythmia(Baseline and within 7 days of completing the 12-week intervention)
  • Diastolic blood pressure(Baseline and within 7 days of completing the 12-week intervention)
  • Brachial diameter(Baseline and within 7 days of completing the 12-week intervention)
  • Maximal carotid intima-media thickness(Baseline and within 7 days of completing the 12-week intervention)
  • Carotid diameter(Baseline and within 7 days of completing the 12-week intervention)
  • Brachial flow-mediated dilation(Baseline and within 7 days of completing the 12-week intervention)
  • Heart rate(Baseline and within 7 days of completing the 12-week intervention)
  • Systolic blood pressure(Baseline and within 7 days of completing the 12-week intervention)
  • Femoral-toe pulse wave velocity(Baseline and within 7 days of completing the 12-week intervention)
  • Low-density lipoprotein(Baseline and within 7 days of completing the 12-week intervention)
  • Total cholesterol : high-density lipoprotein ratio(Baseline and within 7 days of completing the 12-week intervention)
  • Vascular age(Baseline and within 7 days of completing the 12-week intervention)
  • Carotid-femoral pulse wave velocity(Baseline and within 7 days of completing the 12-week intervention)
  • Fibrinogen(Baseline and within 7 days of completing the 12-week intervention)
  • Total cholesterol(Baseline and within 7 days of completing the 12-week intervention)
  • Triglycerides(Baseline and within 7 days of completing the 12-week intervention)
  • Shear stress during reactive hyperemia(Baseline and within 7 days of completing the 12-week intervention)
  • High-density lipoprotein(Baseline and within 7 days of completing the 12-week intervention)
  • Testosterone(Baseline and within 7 days of completing the 12-week intervention)
  • Framingham Risk Score(Baseline and within 7 days of completing the 12-week intervention)
  • High-sensitivity C-reactive protein(Baseline and within 7 days of completing the 12-week intervention)
  • Fasting glucose(Baseline and within 7 days of completing the 12-week intervention)
  • Modifiable CVD Risk Factor Score(Baseline and within 7 days of completing the 12-week intervention)

研究者

申办方类型
Other
责任方
Sponsor

相似试验